IMNM
Immunome, Inc.
1W: -1.6%
1M: -8.2%
3M: -7.8%
YTD: -2.5%
1Y: +149.1%
3Y: +259.3%
5Y: -38.9%
$20.30
+0.09 (+0.45%)
After Hours: $20.51 (+0.21, +1.03%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Bullish
75
Insider+$1.4M
Congress—
ETF Holdings—
Key Statistics
Market Cap$1.8B
52W Range5.15-27.65
Volume1,442,893
Avg Volume1,554,316
Beta2.19
Dividend—
Analyst Ratings
Company Info
CEOClay Siegall
Employees131
SectorHealthcare
IndustryBiotechnology
IPO Date2020-10-02
Websiteimmunome.com
665 Stockton Drive
Bothell, PA 19341
US
Bothell, PA 19341
US
610 321 3700
About Immunome, Inc.
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
Latest News
Immunome (NASDAQ:IMNM) Director Philip Wagenheim Sells 36,800 Shares
Immunome (NASDAQ:IMNM) Director Philip Wagenheim Sells 28,200 Shares of Stock
Immunome, Inc. (NASDAQ:IMNM) Receives $33.45 Average Target Price from Brokerages
HC Wainwright Brokers Raise Earnings Estimates for Immunome
FY2029 EPS Estimates for Immunome Raised by HC Wainwright
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| WAGENHEIM PHILIP | S-Sale | 28,200 | $20.65 | 2026-03-23 |
| WAGENHEIM PHILIP | S-Sale | 36,800 | $20.47 | 2026-03-20 |
| BIENAIME JEAN JACQUE | P-Purchase | 1,000 | $21.55 | 2026-03-11 |
| BIENAIME JEAN JACQUE | P-Purchase | 1,000 | $22.12 | 2026-03-10 |
| Higgins Jack | G-Gift | 1,000 | — | 2025-12-19 |